Technical Analysis for INO - Inovio Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 2.59 -0.77% -0.02
INO closed down 0.77 percent on Friday, September 13, 2019, on 48 percent of normal volume. It was able to find support at its 50 day moving average. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical INO trend table...

Date Alert Name Type % Chg
50 DMA Support Bullish 0.00%
Doji - Bearish? Reversal 0.00%
Upper Bollinger Band Walk Strength 0.00%
Weak + Overbought Other 0.00%
Weak, Overbought and Reversal Signs Reversal 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
50 DMA Support Bullish -0.77%
Doji - Bearish? Reversal -0.77%
Stochastic Reached Overbought Strength -0.77%

Older signals for INO ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Inovio Pharmaceuticals, Inc., together with its subsidiaries, engages in the discovery and development of synthetic vaccines and immune therapies focusing on cancers and infectious diseases. The company's DNA-based SynCon technology enables the design of vaccines capable of providing cross-protection against new, unmatched strains of pathogens, such as influenza. Its electroporation DNA delivery technology uses controlled electrical pulses to enhance cellular DNA vaccine uptake. The company's clinical programs include human papillomavirus/cervical cancer (therapeutic), avian influenza (preventive), prostate cancer (therapeutic), leukemia (therapeutic), hepatitis C virus, hepatitis B virus, human immunodeficiency virus, and malaria vaccines. It is also advancing preclinical research for a seasonal/pandemic influenza vaccine, as well as other products. Inovio Pharmaceuticals, Inc. has collaboration and license agreements with VGX International, Merck, and ChronTech. The company was formerly known as Inovio Biomedical Corporation and changed its name to Inovio Pharmaceuticals, Inc. in May 2010. Inovio Pharmaceuticals, Inc. was founded in 1983 and is headquartered in Blue Bell, Pennsylvania.
Medicine Medical Specialties Infectious Diseases Cancers Prostate Cancer Influenza Vaccination Leukemia Vaccines Virus Influenza Vaccine Malaria Virology Seasonal/Pandemic Influenza Universal Flu Vaccine
Is INO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 6.3
52 Week Low 2.03
Average Volume 592,780
200-Day Moving Average 3.5563
50-Day Moving Average 2.5526
20-Day Moving Average 2.29
10-Day Moving Average 2.302
Average True Range 0.149
ADX 32.67
+DI 28.1257
-DI 16.7729
Chandelier Exit (Long, 3 ATRs ) 2.223
Chandelier Exit (Short, 3 ATRs ) 2.477
Upper Bollinger Band 2.6301
Lower Bollinger Band 1.9499
Percent B (%b) 0.94
BandWidth 29.703057
MACD Line -0.0072
MACD Signal Line -0.0795
MACD Histogram 0.0723
Fundamentals Value
Market Cap 233.69 Million
Num Shares 90.2 Million
EPS -1.07
Price-to-Earnings (P/E) Ratio -2.42
Price-to-Sales 9.78
Price-to-Book 3.53
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.77
Resistance 3 (R3) 2.78 2.72 2.74
Resistance 2 (R2) 2.72 2.68 2.72 2.73
Resistance 1 (R1) 2.66 2.65 2.63 2.65 2.72
Pivot Point 2.60 2.60 2.59 2.60 2.60
Support 1 (S1) 2.54 2.56 2.51 2.53 2.46
Support 2 (S2) 2.48 2.53 2.48 2.45
Support 3 (S3) 2.42 2.48 2.44
Support 4 (S4) 2.41